Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 6/20 | 0.36 |
| ▸ | DRD3 | P35462 | 6/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL620130 | 0.88 | HPGDS (0.39) | HTR7KCNH2 | |
| SCHEMBL619997 | 0.86 | KCNH2 (0.39) | HTR7KCNH2PTK2 | |
| SCHEMBL620931 | 0.84 | KCNH2 (0.44) | HTR7DRD2KCNH2PTK2 | |
| SCHEMBL622311 | 0.79 | GSK3B (0.42) | HTR7 | |
| SCHEMBL619993 | 0.79 | HPGD (0.45) | HTR7KCNH2 | |
| SCHEMBL620405 | 0.77 | HPGD (0.47) | KCNH2 | |
| SCHEMBL622110 | 0.77 | MCHR1 (0.38) | HTR7DRD2KCNH2 | |
| SCHEMBL622668 | 0.77 | HPGD (0.44) | HTR7KCNH2 | |
| SCHEMBL619652 | 0.77 | HPGD (0.44) | HTR7KCNH2HRH1 | |
| SCHEMBL622667 | 0.77 | HPGD (0.44) | HTR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | C5, C1S, CBR3 | HTR7 3743/4885DRD2 736/4885DRD3 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.